Olverembatinib for newly diagnosed chronic phase CML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests the drug olverembatinib alone for people with newly diagnosed chronic phase CML who have not had much prior treatment. It aims to see how well the drug works and what side effects it may cause.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with Philadelphia chromosome positive or BCR::ABL1 positive CML in early chronic phase.
- You have not taken other CML drugs for more than 30 days, except for hydroxyurea, 1-2 doses of cytarabine, or a short course of a TKI.
- You are in good enough health (ECOG score 0-2) and have adequate liver and kidney function.
- You agree to use effective birth control during the study and for 4 months after, if applicable.
- You do not have severe heart disease or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug, olverembatinib, for people with chronic-phase CML that has not responded well to at least two other TKIs, or who have a specific mutation (T315I). The goal is to see if it can control the leukemia better.
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
This trial tests a combination of two drugs, dasatinib and ropeginterferon, for people newly diagnosed with chronic myeloid leukemia (CML) in its early chronic phase. The goal is to see if the combination works safely and helps control the disease.
This study looks at whether lowering the dose of olverembatinib (from 30 or 40 mg to 20 mg every other day) keeps working well for people with chronic myeloid leukemia who have already had a good response. It aims to see if a lower dose can still control the cancer while possibly reducing side effects.
This trial tests a new combination of three drugs (a third-generation TKI, azacitidine, and a Bcl-2 inhibitor) for people with chronic myeloid leukemia that has progressed to a more advanced phase (myeloid blast phase). The goal is to see if this combination is safe and effective.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
Hear when a new Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.